瑟瑞妥单抗

瑟瑞妥单抗
单克隆抗体
种类?
目標HER3
臨床資料
其他名稱MM-121
ATC碼
  • 未分配
识别信息
CAS号1334296-12-6
IUPHAR/BPS
ChemSpider
  • none
UNII
KEGG
化学信息
化学式C6340H9810N1690O1986S52
摩尔质量143,151.18 g·mol−1

瑟瑞妥单抗（INN：Seribantumab[1]；开发代号：MM-121）是一种单克隆抗体，设计用于治疗癌症。[2]它与HER3的胞外结构域结合，阻断NRG1结合，从而阻止受体的激活。[3]

该药物由赛诺菲/梅里马克制药公司（英语：Merrimack Pharmaceuticals）开发。

参考资料

[编辑]
  1. ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 108 (PDF). WHO Drug Information. 2012, 26 (4) [2024-03-01]. （原始内容存档 (PDF)于2016-05-18）. 
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Seribantumab, American Medical Association.
  3. ^ Rendell A, Thomas-Bland I, McCuish L, Taylor C, Binju M, Yu Y. Targeting Tyrosine Kinases in Ovarian Cancer: Small Molecule Inhibitor and Monoclonal Antibody, Where Are We Now?. Biomedicines. August 2022, 10 (9): 2113. PMC 9495728 可免费查阅. PMID 36140214. doi:10.3390/biomedicines10092113 可免费查阅.